Arrowhead Pharmaceuticals, Inc.
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for…
Biotechnology
US, Pasadena [HQ]
FA
Fundamental Analysis · Most Recent Quarter
A dedicated fundamental analysis might help you to get a quick overview
of the
financial stability. It is important to understand the
FA Algorithm
and the criterias before valuing it as a top-tier resource.
Fundamentals
Valuation
| Metric | Q1 | Q2 | Δ in % | |
|---|---|---|---|---|
| EV/EBITDA | -18.96 | -30.85 | -25.94 | |
| Graham Fair Price | 46.94 | 9.47 | 6.45 | |
| PEG | 36.54 | 0.39 | -0.29 | |
| Price/Book | -64.88 | 7.20 | 20.49 | |
| Price/Cash Flow | -56.22 | -27.53 | -17.62 | |
| Prices/Earnings | -12.32 | -6.95 | -6.18 | |
| Price/Sales | inf | 0.00 | 925.63 | |
| Price/FCF | -56.22 | -27.53 | -17.62 | |
| Naive Interpretation | member | |||
01 - Valuation ·
Weak
Fundamentals
Profitability
| Metric | Q1 | Q2 | Δ in % | |
|---|---|---|---|---|
| Gross Profit Margin | inf | 0.00 | -0.20 | |
| Operating Margin | inf | 0.00 | -38.45 | |
| ROA | 38.16 | -0.13 | -0.21 | |
| ROE | -0.83 | -0.26 | 68.73 | |
| ROIC | -0.48 | -0.16 | 66.16 | |
| Naive Interpretation | member | |||
02 - Profitability ·
Not Interpreted
Fundamentals
Financial Growth
| Metric | Q1 | Q2 | Δ in % | |
|---|---|---|---|---|
| Debt QOQ | 2.37 | 0.03 | 7918.65 | |
| Dividends QOQ | 0.00 | 0.00 | 0.00 | |
| EBIT QOQ | -0.26 | 0.08 | -70.89 | |
| EPS QOQ | -0.22 | 0.18 | -17.74 | |
| FCF QOQ | -1.09 | 0.32 | -70.51 | |
| Revenue QOQ | -0.78 | -1.00 | -28.30 | |
| Naive Interpretation | member | |||
03 - Financial Growth ·
Bad
Fundamentals
Leverage & Liquidity
| Metric | Q1 | Q2 | Δ in % | |
|---|---|---|---|---|
| Assets Turnover | n.A. | n.A. | n.A. | |
| Days Inventory Outstanding (DIO) | 0.00 | 0.00 | 0.00 | |
| Days Sales Outstanding (DSO) | 0.00 | 0.00 | 0.00 | |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | |
| Debt/Capitalization | 0.43 | 0.37 | -12.55 | |
| Quick Ratio | 3.46 | 8.03 | 132.19 | |
| Naive Interpretation | member | |||
04 - Leverage & Liquidity ·
Weak
Fundamentals
Per Share Metrics
| Metric | Q1 | Q2 | Δ in % | |
|---|---|---|---|---|
| Book Value | 1.49 | 3.92 | 162.78 | |
| Cash | 2.05 | 4.24 | 106.91 | |
| Capex | -0.64 | -0.28 | 56.76 | |
| Free Cash Flow | -1.74 | -1.03 | 40.92 | |
| Revenue | 0.03 | 0.00 | inf | |
| Naive Interpretation | member | |||
05 - Per Share Metrics ·
Best
Fundamentals
Financial Health
06 - Financial Health ·
Bad